DOI: 10.1055/s-00050348

Indian Journal of Medical and Paediatric Oncology


Saura C, Oliveira M, Feng YH, Dai MS, Hurvitz SA, Kim SB.
Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

J Clin Oncol 2019;
37: 1002

Download Bibliographical Data